**Biodesix Corporate Backgrounder**

**Founded**: 2006

**Business Objective**: Biodesix was founded in 2006 to develop blood-based diagnostic tests that address important clinical questions in cancer care. By interpreting a patient’s tumor and immune profile with the power of artificial intelligence from a simple blood draw, Biodesix provides more clinically relevant information to help physicians and patients fight cancer, quickly and accurately. In 2016, the company focused its clinical diagnostic efforts to provide solutions that concentrate on the continuum of lung cancer patient care from early diagnosis of lung nodules through late stage cancer. The company also partners with the world’s leading biotechnology and pharmaceutical companies to develop companion diagnostics. Biodesix acquired Integrated Diagnostics, Inc. in 2018 and Oncimmune’s U.S. operations in 2019, expanding its commercially available blood-based lung nodule tests to support more informed treatment decisions.

**Products**: Biodesix is the first company to offer four best-in class, blood-based tests for patients with lung cancer or suspicious lung nodules. The VeriStrat® proteomic test has been commercially available to the U.S. market since 2009 and the GeneStrat® genomic test has been available since 2015. The Biodesix Lung Reflex® testing strategy became commercially available in 2016, combining both VeriStrat and GeneStrat test results to support diagnostic and treatment guidance decisions for non-small cell lung cancer (NSCLC) patients in 72 hours. The Nodify XL2™ proteomic test, launched in September 2019, helps physicians identify patients with likely benign lung nodules who may benefit from CT surveillance. The Nodify CDT™ proteomic test, launched in March 2020, helps physicians identify patients with likely malignant lung nodules who may benefit from timely intervention. The Nodify Lung™ Nodule Risk Assessment testing solution, launched in March 2020 alongside Nodify CDT, incorporates both Nodify XL2 and Nodify CDT tests from a single blood draw to reclassify risk of malignancy of incidental lung nodules, enabling physicians to triage patients to the most appropriate course of action.

**Pipeline**: The BDX-012 test, a blood-based proteomic classifier is designed to identify patients who are unlikely to benefit from anti-PD-1 monotherapy, but who may be considered for alternative treatment strategies including novel immunotherapy combinations.

Media Resources:

Scott Hutton, CEO

Robin Harper Cowie, CFO

Bobbi Coffin, CMO

Media Contact:

Jordona Jackson Smith  
(805) 674-7347  
[Jordona@jacksonbio.com](mailto:Jordona@jacksonbio.com)